LAM
TNGX icon

L2 Asset Management’s Tango Therapeutics TNGX Stock Holding History

L2 Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,411
Closed -$1.43K – 234
2023
Q3 		$1.43K Buy
+16,411
New +$100K ﹤0.01% 203

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

L2 Asset Management's TNGX Position: Q4 2023 in Review

L2 Asset Management sold out of Tango Therapeutics (TNGX) in Q4 2023, closing a stake of 16,411 shares — an estimated $1.43K sold.

L2 Asset Management first reported a position in TNGX in Q3 2023 and held it in 1 quarter. The position peaked at $1.43K in Q3 2023. 121 funds tracked by Wall St. Rank hold TNGX as of Q4 2023.

  • L2 Asset Management reported no remaining Tango Therapeutics position as of Q4 2023 after selling out during the quarter.
  • L2 Asset Management sold 16,411 Tango Therapeutics shares in Q4 2023, an estimated $1.43K.
  • L2 Asset Management first reported a position in Tango Therapeutics in Q3 2023 and held it in 1 quarter.
  • L2 Asset Management's Tango Therapeutics position peaked at $1.43K in Q3 2023.
  • 121 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2023.

Based on L2 Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.